Cargando…

Advances in Antioxidant Applications for Combating (131)I Side Effects in Thyroid Cancer Treatment

Thyroid cancer is the most common endocrine cancer, and its prevalence has been increasing for decades. Approx. 95% of differentiated thyroid carcinomas are treated using (131)iodine ((131)I), a radionuclide with a half-life of 8 days, to achieve optimal thyroid residual ablation following thyroidec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Li, Ma, Jiahui, Lei, Pengyu, Yi, Jia, Ma, Yilei, Huang, Zhongke, Wang, Tingjue, Ping, Haiyan, Ruan, Danping, Sun, Da, Pan, Hongying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303824/ https://www.ncbi.nlm.nih.gov/pubmed/37368629 http://dx.doi.org/10.3390/toxics11060529

Ejemplares similares

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Transcriptional response to (131)I exposure of rat thyroid gland
por: Rudqvist, Nils, et al.
Publicado: (2017)

Dosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models
por: Josefsson, Anders, et al.
Publicado: (2014)

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

Iodine-131 and Thyroid Function
por: Sun, Wenjie
Publicado: (2014)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

Psychological impact of (131)I radioprotection measures on thyroid cancer patients
por: BARBUS, ELENA, et al.
Publicado: (2018)

I(131) Accumulation in Hydrocele in the Setting of Metastatic Papillary Carcinoma Thyroid
por: Seetharam, SJ, et al.
Publicado: (2022)

Gut microbiota is associated with response to (131)I therapy in patients with papillary thyroid carcinoma
por: Zheng, Lei, et al.
Publicado: (2022)

Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment
por: Hussein, Osama, et al.
Publicado: (2013)

SAT510 I-131 Therapy with Dosimetry for Advanced Thyroid Carcinoma: Recombinant TSH vs Thyroid Hormone Withdrawal
por: Awad, Dana, et al.
Publicado: (2023)

FDG PET Predicts the Effects of (131)I and Prognosis for Patients with Bone Metastases from Differentiated Thyroid Carcinoma
por: Wang, Danyang, et al.
Publicado: (2020)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Analysis of factors influencing the clinical outcome after surgery and (131)I therapy in patients with moderate-risk thyroid papillary carcinoma
por: Li, Yixuan, et al.
Publicado: (2022)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Prediction of thyroidal (131)I effective half-life in patients with Graves' disease
por: Zhang, Ruiguo, et al.
Publicado: (2017)

Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Oral, Aylin, et al.
Publicado: (2018)

Thyroid dose assessments due to inhalation of (131)I for nuclear medicine workers
por: Liu, Gang, et al.
Publicado: (2022)

A Neck-Thyroid Phantom with Small Sizes of Thyroid Remnants for Postsurgical I-123 and I-131 SPECT/CT Imaging
por: Michael, Konstantinos, et al.
Publicado: (2023)

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
por: Zhang, Haiying, et al.
Publicado: (2014)

MnTnBuOE-2-PyP treatment protects from radioactive iodine (I-131) treatment-related side effects in thyroid cancer
por: Patel, Anery, et al.
Publicado: (2019)

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident
por: Brenner, Alina V., et al.
Publicado: (2011)

Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure
por: Rudqvist, Nils, et al.
Publicado: (2015)

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Palaniswamy, Shanmuga S., et al.
Publicado: (2018)

MON-559 Inappropriate Dosing of I-131 in Non-Metastatic Differentiated Thyroid Cancer
por: Alzenaidi, Ahlam, et al.
Publicado: (2019)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis
por: Lin, Shang, et al.
Publicado: (2021)

Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for (131)I Administration
por: Gomes-Lima, Cristiane J, et al.
Publicado: (2022)

I-131 Avid Tumor Thrombus in a Case of Poorly Differentiated Thyroid Cancer
por: Gill, Sana Munir, et al.
Publicado: (2023)

Usefulness of second (131)I treatment in biochemical persistent differentiated thyroid cancer patients
por: Gambale, Carla, et al.
Publicado: (2023)

Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on (131)I-SPECT/CT
por: Wang, Feng, et al.
Publicado: (2021)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

Interventional therapy for human breast cancer in nude mice with (131)I gelatin microspheres ((131)I-GMSs) following intratumoral injection
por: Li, Chuan-Chao, et al.
Publicado: (2014)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Effect of (131)I ‘clear residual thyroid tissue’ after surgery on the function of parathyroid gland in differentiated thyroid cancer
por: ZHAO, ZHI-HUA, et al.
Publicado: (2015)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
por: Shinto, Ajit S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_es6jb5nr4j92tfruou5kvt09ao